Diabetes Obesity and Metabolism, Год журнала: 2024, Номер unknown
Опубликована: Сен. 23, 2024
We evaluated the efficacy and safety of cofrogliptin, a novel dipeptidyl peptidase-4 inhibitor taken once every 2 weeks (Q2W), compared with linagliptin (taken daily) in patients type diabetes inadequately controlled on metformin China.
Язык: Английский
International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(17), С. 13381 - 13381
Опубликована: Авг. 29, 2023
Diabetes mellitus is a chronic multifaceted disease with multiple potential complications, the treatment of which can only delay and prolong terminal stage disease, i.e., type 2 diabetes (T2DM). The World Health Organization predicts that will be seventh leading cause death by 2030. Although many antidiabetic medicines have been successfully developed in recent years, such as GLP-1 receptor agonists SGLT-2 inhibitors, single-target drugs are gradually failing to meet therapeutic requirements owing individual variability, diversity pathogenesis, organismal resistance. Therefore, there remains need investigate pathogenesis T2DM more depth, identify targets, provide improved glycemic control solutions. This review presents an overview mechanisms action development latest agents targeting years. It also discusses emerging target-based therapies new targets emerged within last three aim our theoretical basis for further advancement targeted T2DM.
Язык: Английский
Процитировано
45
International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(2), С. 1646 - 1646
Опубликована: Янв. 13, 2023
Diabetes Mellitus is a multifactorial disease with critical impact worldwide. During prediabetes, the presence of various inflammatory cytokines and oxidative stress will lead to pathogenesis type 2 diabetes. Furthermore, insulin resistance chronic hyperglycemia micro- macrovascular complications (cardiovascular disease, heart failure, hypertension, kidney atherosclerosis). The development through years pharmacological options allowed us reduce persistence diabetic complications. This review aims highlight specific mechanisms which new treatments for diabetes improve cardiovascular outcomes.
Язык: Английский
Процитировано
27
Talanta, Год журнала: 2025, Номер unknown, С. 127790 - 127790
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
1
Frontiers in Pharmacology, Год журнала: 2024, Номер 15
Опубликована: Фев. 6, 2024
The global prevalence of diabetes mellitus (DM) has led to widespread multi-system damage, especially in cardiovascular and renal functions, heightening morbidity mortality. Emerging antidiabetic drugs sodium-glucose cotransporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 (DPP-4i) have demonstrated efficacy preserving cardiac function, both type diabetic non-diabetic individuals. To understand the exact impact these on cardiorenal protection underlying mechanisms, we conducted a comprehensive review recent large-scale clinical trials basic research focusing SGLT2i, GLP-1RAs, DPP-4i. Accumulating evidence highlights diverse mechanisms including glucose-dependent independent pathways, revealing their potential disease. This provides critical insights into protective effects DPP-4i underscores importance medications mitigating progression complications, broader implications beyond glycemic management.
Язык: Английский
Процитировано
7
Frontiers in Pharmacology, Год журнала: 2024, Номер 15
Опубликована: Фев. 9, 2024
Insulin resistance in brain and amyloidogenesis are principal pathological features of diabetes-related cognitive decline development Alzheimer’s disease (AD). A growing body evidence suggests that maintaining glucose under control diabetic patients is beneficial for preventing AD development. Dipeptidyl peptidase 4 inhibitors (DDP4is) a class novel glucose-lowering medications through increasing insulin excretion decreasing glucagon levels have shown neuroprotective potential recent studies. This review consolidates extant from earlier new studies investigating the association between DPP4i use, AD, other outcomes. Beyond DPP4i’s benefits alleviating glucose-lowering, underlying mechanisms neuroprotection with were categorized into following sections: (Ferrari et al., Physiol Rev, 2021, 101, 1,047–1,081): DPP4is on directly ameliorating burden β-amyloid plaques reducing formation neurofibrillary tangles; bioactivity DPP4 substrates including glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), stromal-derived factor-1α (SDF-1α) etc.; pleiotropic effects neuronal cells intracerebral structure anti-inflammation, anti-oxidation, anti-apoptosis. We further revisited recently published epidemiological provided supportive data to compliment preclinical evidence. Given there remains lack completed randomized trials aim at assessing effect progression, this expected provide useful insight inhibition as therapeutic target prevention treatment. The helpful informing rationales future clinical research guiding evidence-based practice.
Язык: Английский
Процитировано
6
Biomedicines, Год журнала: 2022, Номер 10(9), С. 2306 - 2306
Опубликована: Сен. 16, 2022
Dipeptidyl peptidase 4 (DPP4) is a molecule implicated in the regulation of metabolic homeostasis and inflammatory processes, it exerts its main action through enzymatic activity. DPP4 represents enzyme most involved catabolism incretin hormones; thus, activity impacts appetite, energy balance, fine glucose homeostasis. Indeed, inhibitors represent class antidiabetic agents widely used for treatment Type 2 diabetes mellitus (T2DM). also acts as an adipokine mainly secreted by adipose tissue, mostly from mature adipocytes visceral compartment, where autocrine paracrine activities. can disrupt insulin signaling within adipocyte other target cells tissues, favors development proinflammatory environment. This likely at basis presence elevated circulating levels several diseases. In this review, we summarize recent evidence role adipokine-regulating glucose/insulin metabolism fat homeostasis, with particular focus on clinical outcomes associated increased secretion tissue accumulation dysfunction.
Язык: Английский
Процитировано
27
Applied Biochemistry and Biotechnology, Год журнала: 2025, Номер unknown
Опубликована: Янв. 6, 2025
Язык: Английский
Процитировано
0
Annals of Medicine and Surgery, Год журнала: 2025, Номер 87(4), С. 2133 - 2148
Опубликована: Март 7, 2025
Background: Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral antihyperglycemic agents commonly prescribed for type 2 diabetes (T2DM). Due to the intricate relationship between glucose regulation and cardiovascular diseases (CVDs), DPP-4 have attracted attention their safety efficacy. This bibliometric analysis aims provide insights into global research landscape on outcomes (CVOs). Methods: A was performed, using Web of Science Core Collection. Data were analyzed VOSviewer, CiteSpace, Biblioshiny. Results: The United States led in publication output, followed by Japan China. Harvard University Toronto leading institutions. most influential journals Cardiovascular Diabetology Diabetes Obesity & Metabolism. Darren K. McGuire prolific author Rury R. Holman. occurring keyword heart failure. Cluster revealed key thematic areas field, including “incretin-based therapy,” “dipeptidyl inhibition,” “cardiovascular safety.” Emerging clusters, such as “atrial fibrillation,” gained recent years, highlighting evolving investigation. Conclusion: study underscores importance CVOs inhibitors. high frequency keywords “heart failure,” along with terms like “mortality” “risk,” highlights a strong focus complications literature. Our reflected that studies address these critical aspects health, discussing potential role mitigating adverse outcomes, particularly patients T2DM.
Язык: Английский
Процитировано
0
PLoS ONE, Год журнала: 2025, Номер 20(3), С. e0312600 - e0312600
Опубликована: Март 10, 2025
Exploring the possibility of familiar dietary sources as additional diabetes treatments is crucial, especially considering financial difficulties related to mellitus. Using both in vitro and silico techniques, this work aims assess antidiabetic benefits extract from Solanum lasiocarpum Dunal . The evaluations encompass ability scavenge DPPH radicals, inhibition α-amylase, α-glucosidase, DPP-4, cytotoxicity, glucose absorption kinetics. With an IC50 value 0.69 ± 0.14 mg/ml, S. showed encouraging inhibition. values 2.123 mg/ml inhibited enzymes DPP-4. Furthermore, a notable increase (P < 0.05) uptake by L6 myoblasts was observed with administration various combinations. In analysis, including XP docking MM-GBSA, revealed that 10 21 compounds within combination exhibited substantial interactions stable binding capabilities α-amylase DPP-4 proteins, indicating their potential enzyme inhibitors. Therefore, it can be inferred represents promising therapeutic approach for management.
Язык: Английский
Процитировано
0
Molecules, Год журнала: 2022, Номер 27(14), С. 4498 - 4498
Опубликована: Июль 14, 2022
The enzymatic activity of CD26/DPP4 (dipeptidyl peptidase 4/DPP4) is highlighted in multiple studies to play a vital role glucose metabolism by cleaving and inactivating the incretins glucagon-like peptide-1 (GLP) gastric inhibitory protein (GIP). A large number demonstrate that CD26 also plays an integral immune system, particularly T cell activation. extensively expressed cells, such as B NK dendritic macrophages. cleaves regulates numerous chomokines cytokines. inhibitors have been widely used for treatment diabetes mellitus, while it still under investigation therapy immune-mediated diseases. In addition, CD26’s involvement cancer immunology was described. review aims summarize therapeutic effects on diseases, well mechanisms underpin them.
Язык: Английский
Процитировано
20